Search
for

    Learn

    5 / 5 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

      learn Exosomes

      Microscopic delivery system that sends growth-promoting signals to hair follicles

      learn Valproic acid

      an anticonvulsant repurposed for hair loss via histone inhibition

      learn Dexpanthenol

      precursor of vitamin B5 with hair stimulating effects

    Research

    5 / 1000+ results

    Community Join

    5 / 46 results

      community Tretinoin for some men(not all) can cause non-telogen effluvium hair loss

      in Research/Science  2 upvotes 3 weeks ago
      Tretinoin can cause non-telogen hair loss in some men by inducing catagen-like changes in hair follicles and through retinoid toxicity, especially when used with minoxidil. Some users report hair loss even when using retinoids on the face, while others experience benefits when combined with treatments like finasteride and minoxidil.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  44 upvotes 5 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community Switch from fin to dut and its worse

      in Finasteride/Dutasteride  6 upvotes 2 months ago
      Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 2 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.